Last reviewed · How we verify
NCT01764204
Intensive Hospital-based Adverse Drug Reaction Monitoring Study On Patients Treated By Qingkailing Injection In The Next Two Years
trial testing Qingkailing Injection in Adverse Drug Events in 30,840 participants. Completed in 1 January 2018.
1 December 2017
Quick facts
| Lead sponsor | China Academy of Chinese Medical Sciences |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30,840 |
| Start date | 1 January 2013 |
| Primary completion | 1 December 2017 |
| Estimated completion | 1 January 2018 |
| Sites | 48 locations across China |
Drugs / interventions tested
- Qingkailing Injection — full drug profile →
Conditions studied
- Adverse Drug Events — all drugs for Adverse Drug Events →
- Adverse Drug Reactions — all drugs for Adverse Drug Reactions →
Sponsor
China Academy of Chinese Medical Sciences — full company profile →
Who can join
Adults 1 to 80, any sex, with Adverse Drug Events or Adverse Drug Reactions. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
incidence of severe adverse drug reactions
Time frame: 2 years
Sponsor's own description
To highlight the incidence of adverse reactions of Qingkailing Injection.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Baicalin regulates stem cells as a creative point in the treatment of climacteric syndrome.
Wei Q, Hao X, Lau BW, Wang S, et al · · 2022 · cited 5× · PMID 36408261 · DOI 10.3389/fphar.2022.986436 -
Epigenetic Effects of Natural Products in Inflammatory Diseases: Recent Findings.
Yao Q, Wei T, Qiu H, Cai Y, et al · · 2025 · PMID 39513382 · DOI 10.1002/ptr.8364
Verify or expand the search:
- PubMed search for NCT01764204
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Adverse Drug Events
Currently open trials in the same condition.
- NCT07216846 — The Geriatric Emergency Department Pharmacologic Harm Prevention Project · NA · recruiting
Other China Academy of Chinese Medical Sciences trials
Trials by the same sponsor.
- NCT07319338 — Objective Vascular Biomarkers as Triage for Depression in Chronic Atrophic Gastritis · not yet recruiting
- NCT06874738 — A Real-world Clinical Study on the Treatment of Menopausal Syndrome With Liuwei Dihuang Pills · not yet recruiting
- NCT05586048 — Effectiveness of Yiqi Fumai Lyophilized Injection for Acute Heart Failure · unknown
- NCT05138965 — the Method of Cotton Padding Promoting the Rectovaginal Fistula Surgery · completed
- NCT04932395 — Anshen Buxin Liuwei Pills for the Treatment of Cardiac Neurosis · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01764204 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China Academy of Chinese Medical Sciences
- Last refreshed: 15 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01764204.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing